Gilead 1st-qtr 2014 sales nearly double, fuelled by Sovaldi, as net income rockets

23 April 2014

US antivirals major Gilead Sciences (Nasdaq: GILD) posted first-quarter 2014 results after markets closed yesterday, showing that year-on-year sales for the period had nearly doubled to $5.00 billion, up from $2.53 billion for the first quarter of 2013, a great deal more than analysts’ projections of $3.96 billion. Product sales increased to $4.87 billion compared to $2.39 billion for the first quarter of 2013.

Net income for the current quarter was $2.23 billion, or $1.33 per diluted share, compared to $722.2 million, or $0.43 per diluted share, for the first quarter of 2013. Non-generally accepted accounting principles (GAAP) net income, which excludes acquisition-related, restructuring and stock-based compensation expenses, came in at $2.49 billion, or $1.48 per diluted share, compared to $801.9 million, or $0.48 per diluted share for the like 2013 period. This was way above analysts’ average forecasts of $0.56 earnings per share.

Excluding Sovaldi(sofosbuvir), Gilead continues to expect earnings of $0.63 per share to $0.66 per share on net product sales in the range of $11.3 billion and $11.5 billion for the full year. The company’s shares, already up 35% in the past12 months according to Bloomberg, gained 2.9% to $74.99 in extending New York trading yesterday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology